Response letter to SEJ Todd et al. – Early clinical experience of dolutegravir in an HIV cohort in a larger teaching hospital

Abstract

Get full access to this article

View all access options for this article.

References

Todd S, et al. Early clinical experience of dolutegravir in an HIV cohort in a larger teaching hospital. Int J STD AIDS. Epub ahead of print 21 June 2017. DOI: 10.1177/0956462416688127.

Vivancos-Gallego

. Discontinuation of dolutegravir (DTG)-based regimens in clinical practice. J Int AIDS Soc 2016; 19(Suppl 7): Poster abstract P116.

Hoffman

. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med 2017; 18: 56–63.

Postel N, et al. The DOL-ART cohort: providing evidence from real-world data use of dolutegravir-based regimens in routine clinical care in Germany. In: HIV Glasgow, Glasgow, UK, 23–26 October 2016, poster abstract P133.

Walmsley

. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med 2013; 369: 1807–1818.

MHRA. Interactive drug analysis profile for dolutegravir, https://info.mhra.gov.uk/drug-analysis-profiles/dap-selector.html?agency=MHRA (2017, accessed 13 March 2017).